Cisplatin and Pemetrexed With Radiation Followed by Lobectomy

Inclusion Criteria: * Histologically and cytologically confirmed non-squamous NSCLC. * Resectable T3, and or N2 disease (T3N1, and resectable T1-3N2 multi-station non-bulky with no nodal station being more than 2 cm on preoperative workup, T4N0-1 * Resectable T3 includes patients with a satellite lesion in the same lobe as the primary. * Male or Female, aged \> or = 18 years and be able to give informed consent. * Tumor should be technically operable with a lobectomy, bilobectomy or a sleeve resection. * Patient should be medically operable * ECOG Performance Status 0 or 1. * Adequate bone marrow, hepatic and renal function assessed within 28 days * Signed informed consent. * Women of childbearing potential should have negative pregnancy test prior to enrollment to study. * Men with partners in the childbearing age group and women of childbearing potential must use effective contraception while on treatment and for 6 months thereafter. * The ability to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of Pemetrexed. * The ability to take folic acid, Vitamin B12, and dexamethasone according to protocol. * Patients must have a negative MRI or CT Scan of the brain. Exclusion Criteria: * Patients who have had chemotherapy or radiation therapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * Patients may not be receiving any other investigational agents. * History of allergic reactions attributed to compounds or other agents used in study. * Pregnant or lactating women. * Male patients with female sexual partners in the reproductive age group who refuse to use effective methods of contraception will be excluded from the trial. * Patients with concurrent serious infections. * Patients with an unstable or serious concurrent medical condition are excluded. * Presence of third space fluid which cannot be controlled by drainage. * Weight loss \> 10 percent from baseline weight. * HIV-positive patients on combination antiretroviral therapy are ineligible * Patients with hypercalcemia will be excluded. * Patients who require a pneumonectomy will be excluded.